CKD Bio Corp
KRX:063160
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
CKD Bio Corp
Gross Profit
CKD Bio Corp
Gross Profit Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
CKD Bio Corp
KRX:063160
|
Gross Profit
₩28.8B
|
CAGR 3-Years
20%
|
CAGR 5-Years
1%
|
CAGR 10-Years
3%
|
|
|
Yuhan Corp
KRX:000100
|
Gross Profit
₩729.9B
|
CAGR 3-Years
12%
|
CAGR 5-Years
6%
|
CAGR 10-Years
8%
|
|
|
SK Biopharmaceuticals Co Ltd
KRX:326030
|
Gross Profit
₩663.8B
|
CAGR 3-Years
47%
|
CAGR 5-Years
94%
|
CAGR 10-Years
N/A
|
|
|
Hanmi Pharm Co Ltd
KRX:128940
|
Gross Profit
₩884.4B
|
CAGR 3-Years
7%
|
CAGR 5-Years
9%
|
CAGR 10-Years
0%
|
|
|
S
|
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
|
Gross Profit
₩109.4B
|
CAGR 3-Years
7%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
|
C
|
Caregen Co Ltd
KOSDAQ:214370
|
Gross Profit
₩52.2B
|
CAGR 3-Years
0%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
CKD Bio Corp
Glance View
CKD Bio Corp. engages in the development and manufacture of active pharmaceutical ingredients. The company is headquartered in Seoul, Seoul. The company went IPO on 2001-12-11. The firm mainly provides antibiotic ingredients, consisting of demethylchlortetracyclines (DMCTs) and rifampicins. The company also provides immunosuppressive agents, including cyclosporin and tacrolimus; remedies for diabetes, such as acarbose, and potassium clavulanate used for beta-lactam inhibitors. The firm distributes its products within domestic market and to overseas markets, such as America, China, Europe, Africa, Southeast Asia, Latin America and the Middle East.
See Also
What is CKD Bio Corp's Gross Profit?
Gross Profit
28.8B
KRW
Based on the financial report for Dec 31, 2025, CKD Bio Corp's Gross Profit amounts to 28.8B KRW.
What is CKD Bio Corp's Gross Profit growth rate?
Gross Profit CAGR 10Y
3%
Over the last year, the Gross Profit growth was -20%. The average annual Gross Profit growth rates for CKD Bio Corp have been 20% over the past three years , 1% over the past five years , and 3% over the past ten years .
